Titan Company Limited has officially launched beYon, its dedicated lab-grown diamond brand, with the first exclusive store opening in Mumbai. The strategic move comes as the company reported robust Q2 FY26 results, with jewellery revenue growing 29% to ₹16,522.00 crore despite challenging macro conditions including elevated gold prices.

Conference Call Announcement for beYon Brand

Titan Company Limited has announced a conference call scheduled for January 7, 2026, from 8:15 AM to 9:00 AM IST to discuss the launch of its new brand 'beYon'. The call will feature senior management discussing the brand launch followed by a Q&A session. The company has issued this announcement under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

beYon Brand Launch and Market Strategy

The beYon brand operates separately from Titan's existing jewellery brands including Tanishq, Mia, and Zoya. Following the Mumbai launch, the company plans to open a second store in Delhi as part of its phased expansion strategy. Lab-grown diamonds, which are physically and chemically identical to natural diamonds, are offered at a 30-40% discount to natural diamonds.

Q2 FY26 Financial Performance

Titan delivered strong quarterly results despite macro headwinds from rising gold prices. The company's jewellery division, led by CEO Ajoy Chawla, reported significant revenue growth while managing margin pressures from elevated gold costs. Chief Financial Officer Ashok Sonthalia noted that forecasting margins remains challenging in the current gold price environment.

Strategic Rationale and Market Positioning

Market expert Sandip Sabharwal believes Titan's entry into lab-grown diamonds represents strategic alignment with global trends. He highlighted that nearly 70% of engagement rings in the US market now feature lab-grown diamonds, demonstrating rapid consumer acceptance when affordability and design converge. The company's evolved stance marks a shift from its cautious approach to active scaling in the current period.

Titan Biotech Ltd has announced a significant corporate action with the setting of February 20, 2026, as the record date for its equity share split. This development represents a strategic move by the pharmaceutical company to restructure its share capital.

Share Split Details

The company has outlined the specific parameters of the share subdivision:

Impact on Shareholders

Under this arrangement, existing shareholders will receive five new equity shares of ₹2.00 face value for every one share of ₹10.00 face value they currently hold. The total value of shareholding will remain unchanged immediately after the split, but the number of shares will increase proportionally.

Corporate Action Timeline

With the record date set for February 20, 2026, shareholders who hold shares on this date will be eligible for the share split. The company has provided advance notice of this corporate action, allowing sufficient time for shareholders to plan accordingly.

Share splits are commonly implemented by companies to enhance share liquidity and make shares more affordable for retail investors, potentially broadening the shareholder base.